苦黄注射液联合注射用丁二磺酸腺苷蛋氨酸治疗黄疸型病毒性肝炎临床研究OA
Clinical Study of Kuhuang Injection Combined with Ademetionine 1,4-Butanedisulfonate for Injection in the Treatment of Icteric Viral Hepatitis
目的 探讨苦黄注射液联合注射用丁二磺酸腺苷蛋氨酸治疗黄疸型病毒性肝炎的临床疗效,以及对患者肝损伤相关蛋白水平的影响.方法 回顾性选取医院 2023 年 1 月至 2025 年 5 月收治的 80 例黄疸型病毒性肝炎患者的临床资料,按治疗方法的不同分为观察组和对照组,各 40 例.在常规治疗基础上,两组患者均予注射用丁二磺酸腺苷蛋氨酸治疗,观察组患者加用苦黄注射液.两组患者均连续治疗 60 d.结果 观察组的总有效率为 92.50%,显著高于对照组的 72.50%(P＜0.05).治疗后,两组患者的临床症状(巩膜黄染、身黄、尿黄、肝区叩痛)积分,肝功能指标直接胆红素、总胆红素、丙氨酸氨基转移酶,炎性因子白细胞介素 6、趋化因子 1、肿瘤坏死因子-α 水平,以及血清自噬相关蛋白 Beclin1、纤维蛋白原样蛋白 1 水平均显著低于治疗前(P＜0.05),且观察组均显著低于对照组(P＜0.05);血清载脂蛋白 AⅠ水平均显著高于治疗前(P＜0.05),且观察组显著高于对照组(P＜0.05).观察组与对照组患者不良反应发生率相当(12.50%比 7.50%,P＞0.05).结论 苦黄注射液联合注射用丁二磺酸腺苷蛋氨酸治疗黄疸型病毒性肝炎的临床疗效良好,可改善患者的临床症状和肝功能,缓解炎性反应,调节肝损伤相关蛋白水平,且安全性较高.
Objective To investigate the clinical efficacy of Kuhuang Injection combined with Ademetionine 1,4-Butanedisulfonate for Injection in the treatment of icteric viral hepatitis,and its effect on the levels of liver injury-related proteins in patients.Methods The clinical data from 80 patients with icteric viral hepatitis admitted to the hospital from January 2023 to May 2025 were retrospectively selected and divided into the observation group and the control group according to different treatment methods,with 40 cases in each group.On the basis of conventional treatment,the patients in the two groups were treated with Ademetionine 1,4-Butanedisulfonate for Injection,while the patients in the observation group were additionally treated with Kuhuang Injection.Both groups were treated continuously for 60 d.Results The clinical total effective rate in the observation group was 92.50%,which was significantly higher than 72.50%in the control group(P＜0.05).After treatment,the clinical symptoms(scleral icterus,yellow skin,yellow urine,and liver area percussion pain)scores,the liver function indexes[direct bilirubin,total bilirubin(TBiL),alanine aminotransferase(ALT)],the levels of inflammatory factors[interleukin-6(IL-6),chemokine 1(CXCL1),and tumor necrosis factor-α(TNF-α)],and the levels of serum autophagy-related protein Beclin1(Beclin1)and fibrinogen-like protein 1(FGL-1)in the two groups were significantly lower than those before treatment(P＜0.05),and those in the observation group were significantly lower than those in the control group(P＜0.05);the levels of serum apolipoprotein A Ⅰ(APOA Ⅰ)in the two groups were significantly higher than those before treatment(P＜0.05),and those in the observation group were significantly higher than the control group(P＜0.05).The incidence of adverse reactions in the observation group was comparable to that in the control group(12.50%vs.7.50%,P＞0.05).Conclusion Kuhuang Injection combined with Ademetionine 1,4-Butanedisulfonate for Injection has good clinical efficacy and safety in the treatment of icteric viral hepatitis,which can improve patients' clinical symptoms and liver function,alleviate inflammatory reactions,and regulate liver injury-related protein levels.
李茂;宋龙辉;杨德胜
安徽省濉溪县人民医院,安徽 淮北 235100安徽省濉溪县人民医院,安徽 淮北 235100安徽省濉溪县人民医院,安徽 淮北 235100
医药卫生
苦黄注射液注射用丁二磺酸腺苷蛋氨酸黄疸型病毒性肝炎肝功能炎性反应肝损伤相关蛋白
Kuhuang InjectionAdemetionine 1,4-Butanedisulfonate for Injectionicteric viral hepatitisliver functioninflammatory reactionliver injury-related proteins
《中国药业》 2026 (11)
106-109,4
安徽省卫生健康科研项目[AHWJ2023BBa20063].
评论